IP Library Granted Patent US 8,673,945
Granted Patent B2
US 8,673,945 · App. 13/140,348 · Granted Mar 18, 2014

Solid pharmaceutical composition comprising amlodipine and losartan

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,945
App. No.
13/140,348
Granted
Mar 18, 2014
Kind
B2
Abstract

The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.

Claims (7)

1. A solid pharmaceutical composition comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone.

2. The composition of claim 1 , wherein the disintegrant is a mixture of sodium starch glycolate and crosspovidone.

3. The composition of claim 1 , wherein the disintegrant is a mixture of sodium starch glycolate and crosscarmellose sodium.

4. The composition of claim 1 , wherein the disintegrant is used in an amount ranging from about 2.5 to about 30% by weight based on the total weight of the composition.

5. The composition of claim 4 , wherein the disintegrant is used in an amount ranging from about 5 to about 15% by weight based on the total weight of the composition.

6. A method for treating cardiovascular disorders comprising administering the solid composition of claim 1 to a subject in need thereof.

7. The method of claim 6 , wherein the cardiovascular disorders are selected from the group consisting of angina pectoris, hypertension, artery vasospasm, deep vein, cardiac hypertrophy, cerebral infarct, congestive heart failure, and myocardial infarction.

Assignments (2)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2011
From: WOO, JONG SOO; PARK, JAE HYUN; KIM, YONG IL; KIM, KYEONG SOO; YIM, HO TAEK; IM, JI HYUN
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 026459/0312 →